title: Human herpes virus 8-negative primary effusion lymphoma with BCL6 rearrangement in a patient with idiopathic CD4 positive T-lymphocytopenia.
abstract: Primary effusion lymphoma (PEL) was initially designated as a body-cavity-based lymphoma and recognized as a distinct clinical entity without a contiguous tumor mass. PEL was first reported in patients with acquired immunodeficiency syndrome (AIDS) and the distinctive feature of PEL originally reported as a B-cell neoplasm characterized by infection of the tumor cells by human herpes virus 8 (HHV-8). However, there have recently been several reports of PEL in patients without human immunodeficiency virus (HIV) or HHV-8 infection.
authors.affiliation: Department of Pathology, National Nagasaki Medical Center, 2-1001-1, Kubara, Omura, Nagasaki 856-8562, Japan. niino522@yahoo.co.jp
authors.forename: D
authors.initials: D
authors.lastname: Niino
authors.forename: K
authors.initials: K
authors.lastname: Tsukasaki
authors.forename: K
authors.initials: K
authors.lastname: Torii
authors.forename: D
authors.initials: D
authors.lastname: Imanishi
authors.forename: T
authors.initials: T
authors.lastname: Tsuchiya
authors.forename: Y
authors.initials: Y
authors.lastname: Onimaru
authors.forename: H
authors.initials: H
authors.lastname: Tsushima
authors.forename: S
authors.initials: S
authors.lastname: Yoshida
authors.forename: Y
authors.initials: Y
authors.lastname: Yamada
authors.forename: S
authors.initials: S
authors.lastname: Kamihira
authors.forename: M
authors.initials: M
authors.lastname: Tomonaga
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D015704:CD4 Antigens / Q000096:biosynthesis*; D004268:DNA-Binding Proteins / Q000235:genetics*; D004417:Dyspnea / Q000175:diagnosis; D015321:Gene Rearrangement; D015658:HIV Infections / Q000175:diagnosis; D019288:Herpesvirus 8, Human / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D016130:Immunophenotyping; D054685:Lymphoma, Primary Effusion / Q000150:complications / Q000235:genetics* / Q000628:therapy; D008231:Lymphopenia / Q000150:complications / Q000628:therapy*; D008297:Male; D010490:Pericardial Effusion; D051560:Proto-Oncogene Proteins c-bcl-6; D013601:T-Lymphocytes / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; C084103:BCL6 protein, human; D015704:CD4 Antigens; D004268:DNA-Binding Proteins; D051560:Proto-Oncogene Proteins c-bcl-6